Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.

Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, Hanna R, Kalaycio M, Sekeres MA, Sobecks R, de Lima M, Majhail NS, Maciejewski J.

Bone Marrow Transplant. 2019 Jan 17. doi: 10.1038/s41409-019-0444-1. [Epub ahead of print]

PMID:
30655603
2.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2. [Epub ahead of print]

PMID:
30635634
3.

BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes.

Abuhadra N, Mukherjee S, Al-Issa K, Adema V, Hirsch CM, Advani A, Przychodzen B, Makhoul A, Awada H, Maciejewski JP, Sekeres MA, Nazha A.

Leuk Lymphoma. 2019 Jan 8:1-4. doi: 10.1080/10428194.2018.1543885. [Epub ahead of print] No abstract available.

PMID:
30618304
4.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S.

Blood. 2018 Dec 3. pii: blood-2018-08-869008. doi: 10.1182/blood-2018-08-869008. [Epub ahead of print]

PMID:
30510081
5.

The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes.

Sekeres MA.

Best Pract Res Clin Haematol. 2018 Dec;31(4):346-350. doi: 10.1016/j.beha.2018.09.001. Epub 2018 Sep 20. Review.

PMID:
30466745
6.

Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes.

Nagata Y, Narumi S, Guan Y, Przychodzen BP, Hirsch CM, Makishima H, Shima H, Aly M, Pastor V, Kuzmanovic T, Radivoyevitch T, Adema V, Awada H, Yoshida K, Li S, Sole F, Hanna R, Jha BK, LaFramboise T, Ogawa S, Sekeres MA, Wlodarski MW, Cammenga J, Maciejewski JP.

Blood. 2018 Nov 22;132(21):2309-2313. doi: 10.1182/blood-2017-05-787390. Epub 2018 Oct 15. No abstract available.

PMID:
30322869
7.

Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.

Othus M, Sekeres MA, Nand S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey E.

Leukemia. 2018 Oct 12. doi: 10.1038/s41375-018-0275-x. [Epub ahead of print]

PMID:
30315234
8.

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).

Sekeres MA, Swern AS, Giagounidis A, List AF, Selleslag D, Mittelman M, Schlegelberger B, Göhring G, Li JS, Sugrue MM, Fenaux P.

Blood Cancer J. 2018 Sep 21;8(10):90. doi: 10.1038/s41408-018-0126-z. No abstract available.

9.

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA.

Cancer. 2018 Dec 15;124(24):4601-4609. doi: 10.1002/cncr.31769. Epub 2018 Oct 5.

PMID:
30289970
10.

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.

Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S.

Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21. No abstract available.

PMID:
30242087
11.

Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Santini V, Lübbert M, Maciejewski J, Machherndl-Spandl S, Magalhaes SMM, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL.

Leuk Res. 2018 Oct;73:51-57. doi: 10.1016/j.leukres.2018.08.022. Epub 2018 Sep 6.

12.

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

Ball B, Komrokji RS, Adès L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T.

Blood Adv. 2018 Aug 28;2(16):2063-2071. doi: 10.1182/bloodadvances.2018015529.

13.

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.

Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA.

Am J Hematol. 2018 Nov;93(11):1301-1310. doi: 10.1002/ajh.25238. Epub 2018 Sep 9.

14.

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK.

Leuk Res. 2018 Nov;74:130-136. doi: 10.1016/j.leukres.2018.07.016. Epub 2018 Jul 19.

PMID:
30055822
15.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

16.

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1468893. [Epub ahead of print] No abstract available.

PMID:
29963936
17.

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.

Migdady Y, Barnard J, Al Ali N, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):528-532. doi: 10.1016/j.clml.2018.05.016. Epub 2018 May 26.

PMID:
29937400
18.

New drugs in AML: uses and abuses.

Estey EH, Gale RP, Sekeres MA.

Leukemia. 2018 Jul;32(7):1479-1481. doi: 10.1038/s41375-018-0168-z. Epub 2018 Jun 6. No abstract available.

PMID:
29875431
19.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

20.

Consequences of mutant TET2 on clonality and subclonal hierarchy.

Hirsch CM, Nazha A, Kneen K, Abazeed ME, Meggendorfer M, Przychodzen BP, Nadarajah N, Adema V, Nagata Y, Goyal A, Awada H, Asad MF, Visconte V, Guan Y, Sekeres MA, Olinski R, Jha BK, LaFramboise T, Radivoyevitch T, Haferlach T, Maciejewski JP.

Leukemia. 2018 Aug;32(8):1751-1761. doi: 10.1038/s41375-018-0150-9. Epub 2018 May 24.

PMID:
29795413
21.

Cancer research in the United States: A critical review of current status and proposal for alternative models.

Kantarjian HM, Prat F, Steensma DP, Kurzrock R, Stewart DJ, Sekeres MA, Leveque J.

Cancer. 2018 Jul 15;124(14):2881-2889. doi: 10.1002/cncr.31522. Epub 2018 May 14. No abstract available.

PMID:
29757456
22.

Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al.

Molenaar RJ, Sidana S, Radivoyevitch T, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1889-1892. doi: 10.1200/JCO.2018.78.4074. Epub 2018 May 3. No abstract available.

PMID:
29723096
23.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.

Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121.

24.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219. [Epub ahead of print] No abstract available.

PMID:
29667455
25.

Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.

Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK.

Blood. 2018 May 24;131(21):2402-2405. doi: 10.1182/blood-2018-01-827881. Epub 2018 Apr 16. No abstract available.

PMID:
29661788
26.

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1754-1758. doi: 10.1016/j.bbmt.2018.03.025. Epub 2018 Apr 9.

PMID:
29649620
27.

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.

Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, Advani A, Nand S, Ravandi F, Mukherjee S, Sekeres MA.

Blood. 2018 Jun 21;131(25):2782-2788. doi: 10.1182/blood-2018-01-826693. Epub 2018 Apr 4.

PMID:
29618479
28.

Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee.

Leonard MC, Thyagarajan R, Wilson AJ, Sekeres MA.

Am J Health Syst Pharm. 2018 Apr 1;75(7):451-455. doi: 10.2146/ajhp170531.

PMID:
29572313
29.

Denial's Many Faces.

Boissy AR, Sekeres MA.

J Clin Oncol. 2018 May 1;36(13):1374-1375. doi: 10.1200/JCO.2017.77.3275. Epub 2018 Feb 22. No abstract available.

PMID:
29470141
30.

Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML.

Przychodzen B, Makishima H, Sekeres MA, Balasubramanian SK, Thota S, Patel BJ, Clemente M, Hirsch C, Dienes B, Maciejewski JP.

Oncotarget. 2017 Dec 16;9(2):2050-2057. doi: 10.18632/oncotarget.23328. eCollection 2018 Jan 5.

31.

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.

Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A.

Lancet Haematol. 2018 Mar;5(3):e117-e126. doi: 10.1016/S2352-3026(18)30016-4. Epub 2018 Jan 26.

PMID:
29396092
32.

IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.

Molenaar RJ, Radivoyevitch T, Nagata Y, Khurshed M, Przychodzen B, Makishima H, Xu M, Bleeker FE, Wilmink JW, Carraway HE, Mukherjee S, Sekeres MA, van Noorden CJF, Maciejewski JP.

Clin Cancer Res. 2018 Apr 1;24(7):1705-1715. doi: 10.1158/1078-0432.CCR-17-2796. Epub 2018 Jan 16.

PMID:
29339439
33.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
34.

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.

Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS.

Blood Cancer J. 2018 Jan 10;8(1):4. doi: 10.1038/s41408-017-0040-9.

35.

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.

Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, Angelini D, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Maciejewski JP, Majhail NS, Sekeres MA, Mukherjee S.

J Clin Oncol. 2018 Jun 20;36(18):1831-1839. doi: 10.1200/JCO.2017.75.0232. Epub 2017 Dec 18.

PMID:
29252123
36.

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.

Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G.

Blood Cancer J. 2017 Dec 14;7(12):644. doi: 10.1038/s41408-017-0018-7. No abstract available.

37.

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Al Ali N, Fenaux P, Gore SD, Komrokji R.

Oncotarget. 2017 Jun 14;8(47):81926-81935. doi: 10.18632/oncotarget.18477. eCollection 2017 Oct 10.

38.

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.

Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L.

Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27.

PMID:
29112938
39.

Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.

Molenaar RJ, Pleyer C, Radivoyevitch T, Sidana S, Godley A, Advani AS, Gerds AT, Carraway HE, Kalaycio M, Nazha A, Adelstein DJ, Nasr C, Angelini D, Maciejewski JP, Majhail N, Sekeres MA, Mukherjee S.

Leukemia. 2018 Apr;32(4):952-959. doi: 10.1038/leu.2017.323. Epub 2017 Nov 6.

PMID:
29104287
40.

A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia.

Sakai H, Hosono N, Nakazawa H, Przychodzen B, Polprasert C, Carraway HE, Sekeres MA, Radivoyevitch T, Yoshida K, Sanada M, Yoshizato T, Kataoka K, Nakagawa MM, Ueno H, Nannya Y, Kon A, Shiozawa Y, Takeda J, Shiraishi Y, Chiba K, Miyano S, Singh J, Padgett RA, Ogawa S, Maciejewski JP, Makishima H.

Leukemia. 2018 Mar;32(3):839-843. doi: 10.1038/leu.2017.319. Epub 2017 Nov 3. No abstract available.

PMID:
29099495
41.

Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.

Madanat Y, Sekeres MA.

Semin Hematol. 2017 Jul;54(3):147-153. doi: 10.1053/j.seminhematol.2017.06.001. Epub 2017 Jun 23. Review.

PMID:
28958288
42.

Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.

Balasubramanian SK, Aly M, Nagata Y, Bat T, Przychodzen BP, Hirsch CM, Adema V, Visconte V, Kuzmanovic T, Radivoyevitch T, Nazha A, Mukherjee S, Sekeres MA, Maciejewski JP.

Leukemia. 2018 Feb;32(2):550-553. doi: 10.1038/leu.2017.295. Epub 2017 Sep 22. No abstract available.

PMID:
28935992
43.

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.

Thota S, Patel BJ, Sadaps M, Balasubramanian S, Sanikommu S, Hirsch C, Marotta S, Sekeres MA, Risitano AM, Maciejewski JP.

Br J Haematol. 2018 Oct;183(1):133-136. doi: 10.1111/bjh.14907. Epub 2017 Sep 14. No abstract available.

PMID:
28905372
44.

Origins of myelodysplastic syndromes after aplastic anemia.

Negoro E, Nagata Y, Clemente MJ, Hosono N, Shen W, Nazha A, Yoshizato T, Hirsch C, Przychodzen B, Mahfouz RZ, Kuzmanovic T, Sekeres MA, Makishima H, Ogawa S, Maciejewski JP.

Blood. 2017 Oct 26;130(17):1953-1957. doi: 10.1182/blood-2017-02-767731. Epub 2017 Sep 11. No abstract available.

45.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

46.

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes.

Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, Maciejewski JP, Sekeres MA.

Blood Cancer J. 2017 Sep 1;7(9):e602. doi: 10.1038/bcj.2017.82. No abstract available.

47.

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes.

Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA.

Leukemia. 2017 Dec;31(12):2848-2850. doi: 10.1038/leu.2017.266. Epub 2017 Aug 18. No abstract available.

PMID:
28819282
48.

Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.

Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B, Kalaycio M, Sekeres MA, Smith MR, Hill BT.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):857-862. doi: 10.1016/j.clml.2017.07.003. Epub 2017 Jul 14.

PMID:
28778620
49.

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.

Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G.

Blood. 2017 Sep 28;130(13):1514-1522. doi: 10.1182/blood-2017-06-788497. Epub 2017 Aug 3.

50.

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD.

Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31. Review.

Supplemental Content

Loading ...
Support Center